English

YEAR END REPORT JANUARY – DECEMBER 2011

Report this content

  • Net revenue amounted to SEK 18.3 million (18.5).*
  • The net loss totaled SEK 17.9 million (22.4).  
  • Earnings per stock unit amounted to SEK -0.15 (-0.32).
  • Own sales as a proportion of total sales continued to increase and accounted for 75% (61) of product sales.
  • The Company's cash flow objective is to achieve a positive cash flow before changes in working capital on a monthly basis during the fourth quarter of 2012.
  • The Board proposes that no dividend be paid for 2011.

Fourth quarter

  • Net revenue amounted to SEK 4.0 million (3.5).*
  • The net loss totaled SEK 6.0 million (7.4).  
  • Earnings per stock unit amounted to SEK -0.05 (-0.07).
  • A head of Artimplant USA Inc. has been recruited. He has considerable experience of the US orthopedic market.
  • Own sales in December were the highest to date.

Events after the year-end

  • A proposed new share issue amounting to SEK 28.4 million is guaranteed up to 80%
  • Focus on expanded own sales in the USA following termination of a license agreement.
  • Sales and distribution taken over in the Nordic Region.
  • Total sales in January increased with 32 % compared to last year.

N. B. This is a translation from Swedish. The Swedish version shall always take precedence.

* Figures in brackets refer to the corresponding period last year.

For further information, please contact:
Kjell Thörnbring, CEO
E-mail:        kjell.thornbring@artimplant.com
Telephone:  +46 31 746 56 00, +46 703 11 90 25

Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
 

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on February 9, 2012 at 9:00 AM (Swedish time).

Tags:

artimplant

Documents & Links